Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Mereo BioPharma Group PLC ADR is a biotechnology business based in the US. Mereo BioPharma Group PLC ADR shares (MREO) are listed on the NASDAQ and all prices are listed in US Dollars. Mereo BioPharma Group PLC ADR employs 49 staff and has a trailing 12-month revenue of around $36.5 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $0.82 |
|---|---|
| 52-week range | $0.30 - $2.59 |
| 50-day moving average | $1.22 |
| 200-day moving average | $1.15 |
| Wall St. target price | $577.32 |
| PE ratio | 8.417 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.10 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.8236 from 2022-09-26
| 1 week (2022-09-21) | -11.44% |
|---|---|
| 1 month (2022-08-26) | -37.61% |
| 3 months (2022-06-28) | -45.46% |
| 6 months (2022-03-24) | N/A |
| 1 year (2021-09-27) | -66.79% |
|---|---|
| 2 years (2020-09-28) | -67.95% |
| 3 years (2019-09-27) | 3 |
| 5 years (2017-09-24) | N/A |
Valuing Mereo BioPharma Group PLC ADR stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Mereo BioPharma Group PLC ADR's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Mereo BioPharma Group PLC ADR's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 8x. In other words, Mereo BioPharma Group PLC ADR shares trade at around 8x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $36.5 million |
|---|---|
| Gross profit TTM | $18.6 million |
| Return on assets TTM | -13.82% |
| Return on equity TTM | 34.85% |
| Profit margin | 34.9% |
| Book value | $0.75 |
| Market capitalisation | $98.5 million |
TTM: trailing 12 months
We're not expecting Mereo BioPharma Group PLC ADR to pay a dividend over the next 12 months.
Over the last 12 months, Mereo BioPharma Group PLC ADR's shares have ranged in value from as little as $0.301 up to $2.59. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mereo BioPharma Group PLC ADR's is 0.6112. This would suggest that Mereo BioPharma Group PLC ADR's shares are less volatile than average (for this exchange).
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom. .
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
We’ve rounded up stats on some of the most popular wheat stocks, along with information on how these stocks compare and how to invest.